<div><div></div><div>Profusa updated multiple financing instruments to enhance flexibility and align with Nasdaq rules. The company modified its promissory note with NorthView Sponsor I, keeping $1,869,796 outstanding, removing interest, extending maturity to Dec 31, 2026, and adding an equity conversion at the greater of 95% of the closing price or $0.35 per share, subject to a 4.99% cap. A subsequent amendment added a 19.99% exchange cap unless shareholder approval is obtained, with a commitment to seek such approval within 90 days and periodically thereafter. Separately, Profusa amended a warrant with Ascent Partners Fund to remove automatic conversion or assumption provisions in fundamental transactions, with all other warrant terms unchanged.Agreement 1: Profusa Amends Note; $1.87M Outstanding, Convertible at 95% of Price or $0.35 Floor<ul><li>Agreement type: Note Modification and Conversion Agreement</li><li>Counterparty: NorthView Sponsor I</li><li>Signed / Effective: Apr 24 2026 / same</li><li>Duration / Termination: Until Dec 31 2026</li><li>Reason: Extend maturity and enable equity conversion flexibility</li></ul>Agreement 2: Profusa Adds 19.99% Exchange Cap, Will Seek Shareholder Approval Under Nasdaq Rules<ul><li>Agreement type: Amendment No. 1 to Note Modification and Conversion Agreement</li><li>Counterparty: NorthView Sponsor I</li><li>Signed / Effective: Apr 29 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Comply with Nasdaq shareholder approval requirements</li></ul>Agreement 3: Profusa Amends April 2026 Warrant, Removes Fundamental Transaction Conversion Terms<ul><li>Agreement type: Amendment to Warrant to Purchase Shares of Common Stock</li><li>Counterparty: Ascent Partners Fund</li><li>Signed / Effective: Apr 29 2026 / same</li><li>Duration / Termination: At will</li><li>Reason: Adjust warrant terms for potential transactions</li></ul>Original SEC Filing: Profusa, Inc. [ PFSA ] - 8-K - Apr. 29, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

PFSA

LABU

Profusa has updated its financing terms to enhance flexibility and comply with Nasdaq rules. The company modified its promissory note with NorthView Sponsor I, maintaining $1.87M outstanding, removing interest, and extending maturity to Dec 31, 2026, with an equity conversion at 95% of the closing price or $0.35 per share, subject to a 19.99% cap. Additionally, Profusa amended a warrant with Ascent Partners Fund to remove automatic conversion provisions. Shareholder approval will be sought within 90 days for the exchange cap.

TradingView

Profusa

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

PROFUSA INC. C/WTS 02/08/2027 (TO PUR COM)

Profusa Updates Financing Terms: Note Now Convertible; 19.99% Cap Added; Warrant Amended